Investor relations

IR Contact

Investor related questions may be directed to Cereno Scientific’s CFO Daniel Brodén.

Email: daniel.broden@cerenoscientific.com

Phone: +46 768 66 77 87

Press & news

31 Mar

News

BioStock: FDA grants Cereno Scientific’s lead candidate Orphan Drug Designation Cereno Scientific is accelerating the building of a platform of...

30 Mar

Press release

Cereno Scientific’s Phase II clinical trial postponed due to Covid-19 Due to the global spread of the Sars-cov-2 virus Cereno...

10 Mar

Press release

Cereno Scientific Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension Cereno Scientific today announced that the U.S. Food and Drug...

Calendar

LSX World Congress 2020-02-04 - 2020-02-05

More about us...

Subscribe for corporate news

Follow us on LinkedIn

Follow us on Twitter

Privacy policy

We are proud supporters of World Thrombosis Day. Read more